What Syros Pharmaceuticals, Inc.'s executives and directors are doing with their own shares, from SEC Form 3/4/5 filings — separating what the filings state (awards, withholding, disclosed plans) from what only the pattern of dates shows.
| 3 months | 12 months | |
|---|---|---|
| Open-market buys | 0 | 0 |
| Sells | 0 | 0 |
| Total trades | 0 | 0 |
| 3 months | 12 months | |
|---|---|---|
| Acquired | 0 | 0 |
| Disposed | 0 | 0 |
| Net activity | +0 | +0 |
View rich charts and dive into the patterns of specific insiders — who is accumulating, who is winding down, and which sale explanations the filings actually support.
| Insider | Relation | Date | Transaction | Shares | Price | Value | Shares held |
|---|---|---|---|---|---|---|---|
| Simonian Nancy A | Director | Dec 02 | Open-market sale · S | −37,070 | $0.27 | −$10K | 4,000 |
| Simonian Nancy A | Director | Nov 25 | Open-market sale · S | −134,713 | $0.27 | −$35.7K | 41,070 |
| Quirk Gerald E | Chief Legal & Compliance Offic | Nov 19 | Open-market sale · S | −46,657 | $0.22 | −$10.3K | 0 |
| Haas Jason | Chief Financial Officer | Nov 18 | Open-market sale · S | −137,803 | $0.21 | −$29K | 0 |
| Chee Conley | President & CEO | Nov 18 | Open-market sale · S | −134,797 | $0.20 | −$26.9K | 0 |
| Stephens Kristin | Chief Development Officer | Nov 18 | Open-market sale · S | −36,133 | $0.22 | −$7.95K | 0 |
| Roth David | Chief Medical Officer | Nov 18 | Open-market sale · S | −12,099 | $0.20 | −$2.38K | 0 |
| Haas Jason | Chief Financial Officer | Oct 31 | Withheld — tax / exercise cost · F | −5,624 | $2.09 | −$11.8K | 137,803 |
| Haas Jason | Chief Financial Officer | Oct 31 | Exercise / conversion · M | +18,875 | — | — | 143,427 |
| Stephens Kristin | Chief Development Officer | Oct 31 | Withheld — tax / exercise cost · F | −6,104 | $2.09 | −$12.8K | 36,133 |
| Stephens Kristin | Chief Development Officer | Oct 31 | Exercise / conversion · M | +17,000 | — | — | 42,237 |
| Chee Conley | President & CEO | Oct 31 | Withheld — tax / exercise cost · F | −8,707 | $2.09 | −$18.2K | 130,797 |
| Chee Conley | President & CEO | Oct 31 | Exercise / conversion · M | +17,000 | — | — | 139,504 |
| Simonian Nancy A | Director | Oct 31 | Exercise / conversion · M | +40,125 | — | — | 175,783 |
| Roth David | Chief Medical Officer | Oct 31 | Withheld — tax / exercise cost · F | −6,776 | $2.09 | −$14.2K | 12,099 |
| Roth David | Chief Medical Officer | Oct 31 | Exercise / conversion · M | +18,875 | — | — | 18,875 |
| Quirk Gerald E | Chief Legal & Compliance Offic | Sep 30 | Withheld — tax / exercise cost · F | −3,100 | $2.10 | −$6.51K | 46,657 |
| Quirk Gerald E | Chief Legal & Compliance Offic | Sep 30 | Exercise / conversion · M | +10,000 | — | — | 49,757 |
| Akkaraju Srinivas | Director | Sep 16 | Exercise / conversion · M | +2,667 | — | — | 9,333 |
| Young Richard A | Director | Sep 16 | Exercise / conversion · M | +2,667 | — | — | 10,667 |
Loading...
